A Comparative Review of Liquid Biopsy and AI-Powered Precision Medicine in Medulloblastoma: A Paradigm Shift in Diagnosis and Treatment

This study investigates revolutionary advancements in medulloblastoma treatment by combining liquid biopsy with AI-powered precision medicine. Early identification and individualized treatment plans are made possible by these technologies' non-invasive, real-time insights into tumor processes. The objectives of this strategy are to optimize patient-specific therapy, increase diagnostic accuracy, and eventually improve outcomes in pediatric neuro-oncology by examining biomarkers, such as circulating tumor DNA, and using sophisticated AI algorithms to understand complicated multi-omics data. One of the most difficult children brain tumors to diagnose and treat is medulloblastoma. This paper describes a revolutionary integrated strategy that combines liquid biopsy with AI-powered precision medicine to non-invasively monitor tumor dynamics and tailor treatment. In pediatric neuro-oncology, the methods seek to improve patient outcomes by optimizing therapy approaches, improving diagnostic accuracy, and utilizing real-time biomarker monitoring and sophisticated data modeling.